Elicio Therapeutics, Inc.
NASDAQ: ELTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Robert T. Connelly
- Employees
- 32
- Headquarters
- Boston, United States
- IPO year
- 2021
- Market cap
- $76.0M
- Website
- https://elicio.com
Loading ELTX…
Loading profile data…Frequently asked questions about ELTX
What does Elicio Therapeutics, Inc. (ELTX) do?
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers. Its development portfo...
Where does ELTX trade?
Elicio Therapeutics, Inc. (ELTX) trades on the NASDAQ Global Market.
What sector is ELTX in?
Elicio Therapeutics, Inc. (ELTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Elicio Therapeutics, Inc.?
Robert T. Connelly is the chief executive officer of Elicio Therapeutics, Inc. (ELTX).
Where is Elicio Therapeutics, Inc. headquartered?
Elicio Therapeutics, Inc. is headquartered in United States.
Does ELTX pay a dividend?
Elicio Therapeutics, Inc. (ELTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ELTX go public?
Elicio Therapeutics, Inc. (ELTX) completed its initial public offering in 2021.